I am a Senior Director of Business Development at Curia, working with biotech and pharmaceutical companies that are advancing early‑stage biologics and mRNA programs toward the clinic. I partner closely with scientific, CMC, and program leadership teams to help translate promising assets into executable development strategies with a clear path to IND submission. [office.com] In my current role, I focus on early‑phase drug substance development and clinical manufacturing support for monoclonal antibodies, bispecifics, fusion proteins, and mRNA‑based therapeutics. Much of my work centers on first‑in‑human and Phase I programs, including cell line and process development, early scale‑up, tech transfer planning, and alignment of development activities with regulatory expectations. [office.com] I particularly enjoy working with emerging and growth‑stage companies at critical inflection points, such as preparing for IND‑enabling activities, reassessing CMC strategy after preclinical or early clinical results, or selecting a CDMO partner for initial GMP supply. At CPhI America, I am looking forward to meeting teams who are evaluating early‑phase development and manufacturing partners and value a collaborative, scientifically grounded, and execution‑focused approach. [office.com]